tbio-4101
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2022 (NCT05576077)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06236425 | Phase 1 | Mar 14, 2024 | Turnstone Biologics, Inc., University of South Florida |
| NCT05628883 | Phase 1 | Nov 8, 2022 | Turnstone Biologics, Inc., University of South Florida |
| NCT05576077 | Phase 1 | Oct 30, 2022 | Turnstone Biologics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Turnstone Biologics, Inc. | For profit | 3 | 1 | 1 | 2022 |
| University of South Florida | Academic/Hospital | 2 | 2 | 1 | 2022 |
2 organizations
Page 1 / 1